General World News

A top Gilead exec told us the story behind the biotech’s unusual $5.1 billion deal that’s the exact opposite of a Big Pharma trend

biotech lab medical samples pharma biotech

  • The biopharmaceutical company Gilead just struck a $5.1 billion partnership with the Belgian biotech Galapagos that helps boost its pipeline of experimental drugs.
  • The deal dates back to a casual meeting in January, with six months of negotiations following under the codename “Project Eagles,” Gilead exec Andrew Dickinson told Business Insider.
  • The agreement was finalized the night of a big party held to celebrate Galapagos’s 20th anniversary, he said.
  • In an age of pharma mega-deals, such a big-ticket partnership is relatively unusual — and it was difficult to execute, Dickinson told us.
  • Click here for more BI Prime stories.

The read more >>>

Source:: BusinessInsider.Com